The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Cytoplasmic and membranous staining of varying intensity was observed within the same tumor type in several tumors, ranging from negative to strong positivity. A majority of gastric and liver cancers and several cases of breast, ovarian and urothelial cancers showed strong membranous and cytoplasmic staining. Malignant glioma, lymphoma, melanoma and skin, testis and renal cancers were negative.
Malignant cells were mainly negative except for a few cases of hepatocellular carcinomas, adenocarcinomas in lung, colorectal and breast cancers which showed moderate cytoplasmic staining.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
